Having trouble accessing articles? Reset your cache.

Early Pfizer data from DGAT2-targeting NASH program lay groundwork for monotherapy and combos

Eearly Pfizer data from DGAT2-targeting NASH program lay groundwork for monotherapy, combos

Pfizer thinks Phase I and preclinical data from its DGAT2 program suggest the target could hit NASH's three mechanistic pillars -- dysregulated metabolism, inflammation and fibrosis. The pharma is advancing a next-generation compound both alone and

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE